Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
CTI, Chroma announce final results from tosedostat phase II study on AML

CTI, Chroma announce final results from tosedostat phase II study on AML

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients

Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients

DNA sequencing identifies new altered genes that drive CLL

DNA sequencing identifies new altered genes that drive CLL

Study demonstrates that bone marrow and PBSC result in similar patient survival

Study demonstrates that bone marrow and PBSC result in similar patient survival

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Study: One kind of leukemia sometimes masquerades as another

Study: One kind of leukemia sometimes masquerades as another

KPT-SINE shows promise against CLL

KPT-SINE shows promise against CLL

Plexxikon announces scientific findings from PLX3397 preclinical studies on AML

Plexxikon announces scientific findings from PLX3397 preclinical studies on AML

Technique expands scarce resources used for cord blood transplant procedure

Technique expands scarce resources used for cord blood transplant procedure

Treatment with leukemia patients' own cells may prevent infections after chemotherapy

Treatment with leukemia patients' own cells may prevent infections after chemotherapy

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

Research examines novel treatment techniques for hemophilia B, VTE

Research examines novel treatment techniques for hemophilia B, VTE

Onconova announces data from five rigosertib clinical trials on MDS

Onconova announces data from five rigosertib clinical trials on MDS

Re-treatment with rituximab may benefit patients with LTB follicular lymphoma

Re-treatment with rituximab may benefit patients with LTB follicular lymphoma

PCI-32765 is highly active and well tolerated in patients with CLL

PCI-32765 is highly active and well tolerated in patients with CLL

Onyx announces data from three carfilzomib studies on RRMM

Onyx announces data from three carfilzomib studies on RRMM

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.